ASTRAZENECA PHARMA Surges by 13%; BSE HEALTHCARE Index Up 5.2%
March 20, 2020 03:02 PM

ASTRAZENECA PHARMA share price has zoomed 13% and is presently trading at Rs 2,429.

Meanwhile, the BSE HEALTHCARE Index is at 12,166 (up 5.2%).

Among the top Gainers in the BSE HEALTHCARE Index today are ASTRAZENECA PHARMA (up 13.3%) and ABBOTT INDIA (up 13.8%).

FDC LTD. (down 0.2%) and AJANTA PHARMA (down 0.3%) are among the top losers today.

Over the last one year, ASTRAZENECA PHARMA has moved up from Rs 1,938 to Rs 2,429, registering a gain of Rs 491 (up 21.3%).

On the other hand, the BSE HEALTHCARE has moved down from 14,270 to 12,166, loss of 2,104 points (down 15.9%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 105.4%), J.B.CHEMICALS (up 56.0%) and IPCA LABS (up 52.3%).

What About the Benchmark Indices?

The BSE Sensex is at 30,418 (up 5.1%).

The top gainers among the BSE Sensex stocks today are ONGC (up 17.7%), HUL (up 11.2%) and RELIANCE IND. (up 10.1%). Other gainers include TCS (up 9.2%) and ULTRATECH CEMENT (up 8.7%). The most traded stocks in the BSE Sensex are ONGC and SBI.

In the meantime, NSE Nifty is at 8,883 (up 5.2%). The top gainers in the NSE Nifty include ONGC (up 17.9%), GAIL (up 14.9%) and BHARTI INFRATEL (up 14.9%). Other gainers include DR. REDDYS LAB (up 11.3%) and HUL (up 11.0%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 38,363 to 30,418, registering a loss of 7,945 points (down 22.48%).

ASTRAZENECA PHARMA Financial Update...

ASTRAZENECA PHARMA net profit down at Rs 144 million for the quarter ended September 2019, compared to a loss of Rs 291 million a year ago. Net Sales declined 3.1% to Rs 2.1 billion during the period as against Rs 2.2 billion in July-September 2018.

For the year ended March 2018, ASTRAZENECA PHARMA reported 29.2% increase in net profit to Rs 259.0 million compared to net profit of Rs 200.0 million during FY17.

Revenue of the company grew 4.3% to Rs 6 billion during FY18.

The current Price to earnings ratio of ASTRAZENECA PHARMA, based on rolling 12 month earnings, stands at 78.5x.